Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools IDH-mutant glioma

IDH-mutant glioma

Programs, trials, and reported response and survival for IDH-mutant glioma.

Data as of 11.07.2026

All studies

Ivosidenib

Ivosidenib Phase 1 (glioma)

Servier · Phase 1 · Completed · Enrollment 174

NCT02073994

ArmPopulationDoseEstimandComparatorEfficacy
Ivosidenib, non-enhancing gliomarecurrent non-enhancing IDH1-mutant gliomaPhase 1 dosesSingle armn/rmedian PFS: 13.6 months, 95% CI 9.2 to 33.2